Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Neoplasms 1Gallbladder Neoplasms 1Digestive System Neoplasms 1Cachexia 1Adenoma 1

Interventions

Capecitabine 6Irinotecan 5Fluorouracil 5Cisplatin 5Oxaliplatin 4Leucovorin 4Gemcitabine 4apatinib 3Sorafenib 3Bevacizumab 3tislelizumab 2pembrolizumab 2Sunitinib 2Radiotherapy 2Paclitaxel 2Immune Checkpoint Inhibitors 2Cyclophosphamide 2Cetuximab 2Aspirin 2Ascorbic Acid 2130-nm albumin-bound paclitaxel 2spartalizumab 1sintilimab 1regorafenib 1pyrotinib 1pemigatinib 1lutetium Lu 177 dotatate 1huachansu 1halofantrine 1guadecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Digestive System Neoplasms × Cholecystectomy × Clear all
NCT04780737 2021-03-03

Prophylactic Cholecystectomy is Not Mandatory in Patients Candidate to the Resection for Small Intestine Neuroendocrine Neoplasms: a Propensity Score-matched and Cost-minimization Analysis

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Completed
230 enrolled
EndocrineGastrointestinalNET

Digestive System Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡